GLP1R and type 2 diabetes mellitus: Because GLP-1 secretion has an incretin mechanism that is independent of plasma glucose concentration, pharmacologic analogs have been developed to improve glycemic efficiency in individuals who have impaired glucose tolerance and type 2 diabetes (T1DM) [13].